[Effect of mebendazole, albendazole and albendazole sulfoxide on glycogen contents of Echinococcus granulosus cysts in infected mice].
Mice infected with protoscoleces of Echinococcus granulosus for 8-9 months were treated ig with mebendazole (Meb) 50 mg.kg-1.d-1, albendazole (Alb) 300 mg.kg-1.d-1 or albendazole sulfoxide (AlbSO) 150 mg.kg-1.d-1 for 1-7 d. The glycogen contents of cyst wall in each drug groups were 1.0 +/- 0.6 - 1.8 +/- 0.9 mg/g, 1.1 +/- 0.9 - 1.8 +/- 0.8 mg/g and 0.8 +/- 0.5 - 1.5 +/- 0.9 mg/g, respectively, which were less than those 2.2 +/- 1.3 - 2.8 +/- 1.3 mg/g of corresponding control groups with respective glycogen reduction rates of 38-55%, 36-51% and 46-62%. After prolongation of treatment course to 10-14 d, the glycogen contents of cyst wall in Meb and AlbSO groups were further decreased, which resulted in glycogen reduction rates of 73% and 69%, respectively. No further decrease of glycogen contents in Alb groups was seen as the glycogen reduction rates sustained in 32%. Histochemical observation showed that the glycogen contents in germinal layer of the cysts decreased significantly or even disappeared during the treatment of Meb, Alb or AlbSO. The results suggested that the effects of Meb and AlbSO on mice infected with secondary cysts of E granulosus were superior to Alb as evaluated by glycogen reduction rate of cyst wall.
Xiao
S H
SH
Institute of Parasitic Diseases, Chinese Academy of Preventive Medicine, Shanghai.
Yang
Y Q
YQ
Guo
H F
HF
Zhang
C W
CW
Jiao
P Y
PY
You
J Q
JQ
Jiao
W
W
D015766:Albendazole / Q000031:analogs & derivatives* / Q000494:pharmacology*; D000818:Animals; D000871:Anthelmintics / Q000494:pharmacology*; D004443:Echinococcosis / Q000188:drug therapy* / Q000378:metabolism; D004446:Echinococcus / Q000187:drug effects*; D005260:Female; D006003:Glycogen / Q000378:metabolism*; D008463:Mebendazole / Q000494:pharmacology*; D051379:Mice
D000871:Anthelmintics; D008463:Mebendazole; D006003:Glycogen; D015766:Albendazole; C027186:albendazole sulfoxide